The investment is 4 billion Yen and expands Sumitomo’s share in the company to 19,55 %. Bonac is a specialist for modified RNA synthesis (Bonac nucleic acids) which exhibit good stability and may lead to novel mucleic acid drugs.

Bonac news release, September 26, 2017